Stifel lowered the firm’s price target on MacroGenics (MGNX) to $5 from $6 and keeps a Hold rating on the shares following earnings and a corporate update. An update from the fully-enrolled LORIKEET trial in chemotherapy-naive mCRPC patients due in the second half represents “a potentially important catalyst,’ particularly given that the current valuation “doesn’t imply any value here,” says the analyst, whose updated model mostly reflects revised financing assumptions.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MacroGenics price target lowered to $3 from $8 at Barclays
- MacroGenics reports Q1 EPS (65c), consensus (69c)
- MGNX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MacroGenics price target lowered to $2 from $4 at H.C. Wainwright
- MacroGenics: Hold Rating Amidst Development Halts and Financial Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue